Protective Effects of (Borago) on Cold Restraint Stress-Induced Gastric Ulcers in Rats: A Pilot Study
Overview
Affiliations
Stress is a typical body's natural defense to a generic physical or psychic change. A specific linking mechanism between ulcer onset and psycho-physical stress prolonged exposure has been reported. We decided to investigate the possible effects of L. (Borago) in preventing physical (stress)-induced gastric ulcers in a rat model. Eighty male Sprague-Dawley rats were randomly divided into 16 groups, pretreated with a control solution, omeprazole (20 mg/kg), Borago methanolic extract (25, 50, 100, 250, and 500 mg/kg), Borago organic extract (50, 100, 250, and 500 mg/kg), Borago aqueous extract (5, 10, 20, 30, and 40 mg/kg), and D(-)-2-Amino-5-phosphonovaleric acid (AP5) (25 mg/kg) and kept in stressful conditions such as water immersion and restraint-induced stress ulcers. The animals were sacrificed and their stomach scored for the severity and the number of gastric ulcers. Methanolic extract (500 mg/kg) significantly reduced both ulcer parameters ( < 0.001 and < 0.01, respectively). Aqueous and organic extract significantly decreased severity score at 5 and 10 mg/kg ( < 0.01 and < 0.001, respectively), and at 250 and 500 mg/kg ( < 0.001), respectively, while gastric ulcers' resulted number significantly reduced only at 10 mg/kg ( < 0.05) and at 500 mg/kg ( < 0.01), respectively. On the other hand, aqueous extract significantly increased the mucosal gastric content of cAMP ( < 0.05) and NR2A and NR2B subunits ( < 0.05 and < 0.01, respectively) at 5 mg/kg. Organic extract showed also a significant cytotoxic effect at 500 and 1,000 mg/kg with a 3T3 cell viability reduction of 43.6% ( < 0.01) and 92.1% ( < 0.001), respectively. Borago aqueous extract at 10 mg/kg could be considered as a potential protective agent against stress-induced ulcers, and it is reasonable to possibly ascribe such protective activity to a modulation of the NR2A and NR2B subunit expression.
Sun H, Li C, Shi Y, Wang Y, Li J, Fan L Front Pharmacol. 2024; 15:1389873.
PMID: 38751777 PMC: 11094298. DOI: 10.3389/fphar.2024.1389873.
Lv H, Xia S, He Y, Qiao C, Liu J, Guo J J Physiol Biochem. 2024; 80(2):465-477.
PMID: 38526704 DOI: 10.1007/s13105-024-01019-w.
Zhang Y, Duan C, Wu S, Ma J, Liu Y, Li W Front Immunol. 2022; 13:936689.
PMID: 36505466 PMC: 9732082. DOI: 10.3389/fimmu.2022.936689.
Foudah A, Aloneizi F, Alqarni M, Alam A, Ayman Salkini M, Abubaker H Pharmaceuticals (Basel). 2022; 15(9).
PMID: 36145310 PMC: 9502456. DOI: 10.3390/ph15091089.
Zhang Y, Wu S, Liu Y, Ma J, Li W, Xu X Front Cell Infect Microbiol. 2021; 11:706849.
PMID: 34722327 PMC: 8551804. DOI: 10.3389/fcimb.2021.706849.